Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Tumors Models, and Response of Tumors Martin Brown April 23, 2012 Cancers comprise more than tumor cells. Do the stromal cells affect the response to radiotherapy? Hanahan and Weinberg, Cell 2011 Endothelial cells should be a prime target in radiotherapy – Julie Denekamp Capillary Endothelial cell •Endothelial cells in tumors are rapidly dividing so will die rapidly after irradiation •One endothelial cell supports 2000 tumor cells! Tumor curability by IR does not depend on the sensitivity of the host (Budach et al, 1993) TD50 assay for in vivo response of tumors (Hewitt and Wilson, 1959) Cell survival curve of leukemia cells irradiated in situ and in vitro (Hewitt & Wilson,1959) Lung colony assay (Hill and Bush) Tumor Growth Delay Assay Tumor growth delay following different radiation doses. Demonstration of Tumor Radiosensitization using TCD50 assay (Sheldon et al, 1974) In vivo/in vitro (excision) assay This is the fastest, cheapest and most accurate assay of the response of the tumor cells. However, it makes the assumption that the response of the cells is not altered by taking them out of the tumor. Demonstration of “hypoxic fraction” in mouse tumors (Rockwell & Kallman, 1972) Spheroids: an in vitro tumor model. Mimics several aspects of tumors -chronic hypoxia adjacent to necrosis -non dividing cells -cell to cell contact -limited diffusion of drugs Tumor Hypoxia results from Differences in the Vasculature between Tumor and Normal Tissues Chronic Hypoxia (HIF-1 staining) in Human Head & Neck Cancers(Aebersold et al, 2001) HIF-1 staining Blood vessels Necrosis Oxygenation of human tumors is usually measured with an oxygen electrode (“Eppendorf”) Oxygen tensions of Normal Tissue and Nodes of Head and Neck Cancers 20 % of Measurements 16 Normal Subcutaneous Tissue 12 8 4 0 Median pO2 0 10 20 30 40 50 60 70 80 90 100 20 16 Tumor 12 8 4 0 0 10 20 30 40 50 60 70 80 90 100 Oxygen Partial Pressure (mm Hg) Median pO2 Values for Tumor and Normal Tissues for 62 Head & Neck Cancer Patients (Le et al 2004) Median pO2 values for Tumor and Normal 0.3 0.2 Proportion of Values 0.1 Tumor Median = 11.8 mmHg Normal Median = 51.9 mmHg 0.0 0 10 20 30 40 50 60 70 80 Median pO2 (mmHg) Effect of Tumor Hypoxia on Local Control of Head and Neck Cancer (Brizel et al, 1999) 63 patients treated. Similar differences for survival and DFS. Oxygenation of Prostate Carcinoma by Eppendorf Electrode Movsas et al, 2001 Parker et al, 2004 Med = 2.4mmHg Med = 4.5 mmHg Effect of tumor hypoxia on outcome of prostate ca to RT (Movsas et al, 2002) Biochemical failure by PSA pO2 = 5.3 mmHg pO2 = 1.0 mmHg Median Oxygen Levels of Human Tumors (Brown & Wilson Nat. Rev. Cancer 4: 437 2004) It is incorrect to think that tumors are composed of hypoxic and aerobic cells. In fact the majority are at intermediate pO2 Hypoxic Intermediate Aerobic 3.0 Koch et al,1984 Whillans and Hunt,1982 OER(p) 2.5 2.0 1.5 1.0 0.1 1 10 100 Oxygen Partial Pressure (p) (mm Hg) When the cells at intermediate hypoxia are considered the predicted survival to 2 Gy fractions is dramatically altered 10 0 Surviving Fraction 10 -1 10 -2 10 -3 10 -4 10% hypoxic cells and intermediate p02 cells with full reoxygenation 10 -5 10 -6 10 -7 10% hypoxic cells with full reoxygenation (binary) 10 -8 10 -9 10 -10 0 No Hypoxic Cells 10 20 30 40 50 60 Total Dose (2 Gy Fractions) Wouters and Brown,1997 Consequences of Tumor Hypoxia for Cancer Treatment • Hypoxic cells are resistant to killing by IR – Extent of hypoxia affects response to radiotherapy • Hypoxia is associated with slowing of proliferation: – Leads to resistance to most anticancer drugs. • Hypoxia promotes and selects for a more malignant phenotype – Hypoxic tumors are more metastatic Hypoxia and proliferation in human H & N tumors (Van der Kogel et al) Green: hypoxia Red: proliferation (IdUrd+) Human Glioblastoma Stained with EF5 (Red) and Ki-67 (Green) (Evans and Koch, 2002) Capillary O2 O2 O2 Surviving Fraction Expect gradient of cell killing from blood vessels to necrosis . Radiation / Chem. Drug 0 50 100 150 Distance from Capillary (µm) X-ray Survival of Cells in SiHa Tumors as a function of Distance from Blood Vessels (Durand & Olive, 1997) Aerobic Hypoxic Expression of hypoxia induced proteins (eg CA IX) can be used in archival tissues as a surrogate for hypoxia. Immunohistochemical staining for CA IX Head and Neck Breast Adenocarcinoma NPC Ovarian Adenocarcinoma Hui et al, 2002 Wykoff et al, 2000 Can we exploit tumor hypoxia? • A drug specifically toxic to hypoxic cells would kill only tumor cells - and the most resistant ones. Preferential Toxicity of Tirapazamine (TPZ) to Hypoxic Cells in vitro O N N N O TPZ Mouse SCCVII cells 1 hr exposure Mouse SCCVII cells 1 hr exposure 10 0 10 -1 10 -2 10 -3 Hypoxia 10 -4 10 -5 0 Air 1000 2000 3000 4000 TPZ Conc (µM) Surviving Fraction 10 0 10 -1 HCR=300 10 -2 10 -3 10 -4 10 -5 0 10 10 1 10 2 10 3 TPZ Conc (µM) 10 4 NH 2 Addition of a Hypoxic Cytotoxin to Standard Treatment Could Exploit Tumor Hypoxia O2 O2 O2 Surviving Fraction Capillary Hypoxic Cytotoxin . Radiation / Chem. Drug Combined 0 50 100 Distance from Capillary (µm) 150 Complementary Killing by TPZ and IR in SiHa Tumors as a function of Distance from Blood Vessels (Durand & Olive, 1997) Combined Aerobic Hypoxic Primary site failure in 92 randomized advanced H&N patients (Peters et al,2007,) PET hypoxia status Treatment P-value RT + cis /no TPZ RT + cis/TPZ NonHypoxic 2/27 (7%) 3/21 (14%) NS Hypoxic 8/18 (44%) 0/26 (0%) 0.0002 P-value 0.008 NS Results of multicenter randomized clinical trial of TPZ with advanced H & N cancer All 863 patients in 89 sites in 16 countries 693 patients without major protocol violations Need to select hypoxic tumors in future trials and have good QA for radiotherapy Rischin et al and Peters et al, JCO, 2010 Patient Numbers Needed to Detect a Change from 40 to 65% Response Rates 10000 90% probability 80% probability Number 1000 of Patients 100 0 20 40 60 80 100 % Patients with Hypoxic Tumors SN30000 is superior to TPZ in multiple tumor models Single doses ( 15 or 20 Gy) Fractionated 8 x 2 Gy SiHa tumor Hicks et al, Clin Cancer Res 2010 Summary • Sensitivity of tumor and normal cells can be assayed quantitatively in situ in experimental systems. • Tumor hypoxia has a major negative impact on the curability of tumors by radiotherapy, and probably also chemotherapy • Tumor hypoxia can be exploited using drugs specifically toxic to hypoxic cells.